The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

The dyad model fosters collaboration between academic specialists and community oncologists, ensuring seamless patient care ...

Yuman Fong, MD, discusses the evolution of colorectal liver metastases management from historical neglect to multimodal ...

Racial and ethnic disparities in pancreatic cancer treatment and survival persist, with minority groups experiencing lower ...

Michael David Chuong, MD, discusses how SBRT has become a leading option for treating patients with colorectal liver ...

Gastrointestinal (GI) Cancers Symposium, Dani Castillo, MD, medical oncologist, City of Hope, shared new research titled, “Impact of metastatic sites and Lauren subtype on survival outcomes of ...

Amid the many barriers to optimal influenza vaccination coverage, Marco del Riccio, MD, of the University of Florence in Italy, emphasizes the importance of prioritizing patients at the highest risk, ...

With Johnson & Johnson’s participation, 15 of 17 companies contacted by the administration over the summer have now signed on ...

With the debut of TrumpRx.gov and other moves, the administration is steering the nation toward a market-driven, “America ...

Elena Elimova, MD, shares efficacy data for zanidatamab in patients with HER2-positive gastroesophageal adenocarcinoma from ...

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant ...

Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care ...